Biogennix Celebrates a Decade of Innovation and Clinical Success

IRVINE, Calif.–(BUSINESS WIRE)–Irvine-based Biogennix, an advanced osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, is celebrating the 10^th anniversary of its first clinical case.

In 2011, Biogennix introduced its novel osteoSPAN™ fusion kits, which consist of two uniquely-sized porous blocks designed to “span” the transverse processes during single-level spine fusion procedures. The osteoSPAN fusion kits remain a unique offering for spine fusion procedures today.

With surgeons embracing the ease of use and clinical outcomes of osteoSPAN fusion kits, Biogennix grew exponentially and over the years has continued introducing new and novel products, including osteoSPAN granules, Morpheus^® moldable bone graft, and later the collagen-enhanced Agilon^® Moldable product line. Through the COVID-19 pandemic, the company continued investing in new product development and introduced its first strip product, Agilon Strip, in April of this year.

The steady success and year-over-year increases of Biogennix’s sales have led to consistent growth for the company, which continues to invest in research and development, and distributor partnerships. The company, which initially focused on spine procedures, has seen steady growth in additional market segments, most notably with foot and ankle surgeons, who are drawn to the company’s solid track record of clinical success and excellent product handling.

“It’s been a highly rewarding ten years of seeing positive clinical outcomes and receiving enthusiastic feedback from surgeons for each of our products,” said Dr. Edwin Shors, President of Biogennix. “As we enter our second decade of clinical innovation, our focus is to continue investing in new product development, strategic partnerships across the US, and manufacturing to keep up with growing demand and so that we can continue to provide new solutions for surgeons.”